Table 2 Associations between ALT/HDL-C and NAFLD status.

From: Utility of the serum alanine aminotransferase to high density lipoprotein cholesterol ratio in evaluating nonalcoholic fatty liver disease and liver fibrosis

 

Model 1

OR (95% CI), P value

Model 2

OR (95% CI), P value

Model 3

OR (95% CI), P value

ALT/HDL-C

7.595 (6.132, 9.407)

< 0.001

8.151 (6.455, 10.294)

< 0.001

2.915 (2.290, 3.709)

< 0.001

Q1 (0.032–0.215)

Reference

Reference

Reference

Q2 (0.216–0.317)

2.040 (1.632, 2.550)

< 0.001

1.936 (1.539, 2.436)

< 0.001

1.419 (1.086, 1.856) 0.010

Q3 (0.318–0.508)

4.054 (3.281, 5.009)

< 0.001

3.862 (3.091, 4.824)

< 0.001

2.253 (1.737, 2.921)

< 0.001

Q4 (0.509–12.500)

10.120 (8.206, 12.480)

< 0.001

11.096 (8.805, 13.984)

< 0.001

4.571 (3.483, 5.999)

< 0.001

P for trend

< 0.001

< 0.001

< 0.001

Subgroup analysis stratified by sex

Men

5.877 (4.502, 7.671)

< 0.001

6.810 (5.138, 9.027)

< 0.001

2.345 (1.747, 3.148)

< 0.001

Q1 (0.056–0.215)

Reference

Reference

Reference

Q2 (0.216–0.317)

1.451 (0.948, 2.222) 0.086

1.392 (0.895, 2.166) 0.142

0.912 (0.536, 1.552) 0.734

Q3 (0.318–0.508)

2.886 (1.963, 4.241)

< 0.001

2.584 (1.730, 3.859)

< 0.001

1.005 (0.617, 1.635) 0.985

Q4 (0.509–12.500)

8.457 (5.828, 12.271)

< 0.001

8.766 (5.918, 12.984)

< 0.001

2.293 (1.418, 3.708)

< 0.001

P for trend

< 0.001

< 0.001

< 0.001

Women

13.243 (8.753, 20.037) < 0.001

12.083 (7.951, 18.360)

< 0.001

3.665 (2.369, 5.670)

< 0.001

Q1 (0.032–0.215)

Reference

Reference

Reference

Q2 (0.216–0.317)

2.351 (1.808, 3.059)

< 0.001

2.187 (1.670, 2.863)

< 0.001

1.566 (1.151, 2.131) 0.004

Q3 (0.318–0.508)

5.217 (4.006, 6.794)

< 0.001

4.756 (3.625, 6.239)

< 0.001

3.046 (2.236, 4.151)

< 0.001

Q4 (0.509–6.087)

11.459 (8.513, 15.423)

< 0.001

10.858 (7.983, 14.768)

< 0.001

5.129 (3.601, 7.305) < 0.001

P for trend

< 0.001

< 0.001

< 0.001

Subgroup analysis stratified by age

< 20

13.030 (7.286, 23.303) < 0.001

12.273 (6.552, 22.990)

< 0.001

2.133 (1.280, 3.555)

0.003

≥ 20, < 40

5.760 (4.146, 8.003)

< 0.001

4.814 (3.379, 6.857)

< 0.001

1.943 (1.345, 2.806)

< 0.001

≥ 40, < 60

9.942 (6.355, 15.554)

< 0.001

9.986 (6.099, 16.353)

< 0.001

3.950 (2.319, 6.727)

< 0.001

≥ 60

9.469 (5.668, 15.818)

< 0.001

8.462 (4.969, 14.411)

< 0.001

4.737 (2.663, 8.424)

< 0.001

Subgroup analysis stratified by BMI

< 25

4.176 (2.315, 7.532)

< 0.001

4.033 (2.182, 7.453)

< 0.001

2.547 (1.466, 4.423)

< 0.001

≥ 25, < 30

4.216 (2.942, 6.043)

< 0.001

4.269 (2.882, 6.322)

< 0.001

3.906 (2.561, 5.957)

< 0.001

≥ 30

3.852 (2.854, 5.198)

< 0.001

2.924 (2.122, 4.029)

< 0.001

1.912 (1.381, 2.646)

< 0.001

Subgroup analysis stratified by Hypertension

YES

7.042 (5.003, 9.912)

< 0.001

6.271 (4.330, 9.081)

< 0.001

3.693 (2.534, 5.380)

< 0.001

NO

7.362 (5.553, 9.762)

< 0.001

7.068 (5.196, 9.614)

< 0.001

2.604 (1.929, 3.516)

< 0.001

Subgroup analysis stratified by T2DM

YES

6.247 (3.615, 10.796)

< 0.001

5.545 (3.081, 9.980)

< 0.001

4.340 (2.308, 8.160)

< 0.001

NO

7.172 (5.672, 9.068)

< 0.001

7.515 (5.817, 9.709)

< 0.001

2.727 (2.097, 3.547)

< 0.001

  1. Model 1: no covariates were adjusted. Model 2: age, gender, and race were adjusted. Model 3: age, gender, race, hypertension, BMI, T2DM, smoke, physical activity level, WC, LSM, DBP, SBP, CRP, fast glucose, fast insulin, HbA1c, TBIL, ALP, GGT, AST, TG, and SUA were adjusted. In the subgroup analysis for gender, the model was not adjusted for gender; in the subgroup analysis for age, the model was not adjusted for age; in the subgroup analysis for BMI, the model was not adjusted for BMI.
Back to article page